otenaproxesul   Click here for help

GtoPdb Ligand ID: 9534

Synonyms: ATB 346 | ATB-346 | ATB-346, (S)- | ATB346
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Otenaproxesul (ATB-346) is a novel, orally administered, gastrointestinal-sparing hydrogen sulfide (H2S)-releasing analgesic and anti-inflammatory drug in clinical trials for osteoarthritis [8]. Structurally it comprises an H2S-releasing moiety covalently linked to a NSAID (naproxen). H2S-releasing NSAIDs are in development for their potential analgesic, anti-inflammatory, cytoprotective and chemopreventative properties [2-3,5-6,9-10].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 93.64
Molecular weight 365.11
XLogP 4.19
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COc1ccc2c(c1)ccc(c2)C(C(=O)Oc1ccc(cc1)C(=S)N)C
Isomeric SMILES COc1ccc2c(c1)ccc(c2)[C@@H](C(=O)Oc1ccc(cc1)C(=S)N)C
InChI InChI=1S/C21H19NO3S/c1-13(21(23)25-18-8-5-14(6-9-18)20(22)26)15-3-4-17-12-19(24-2)10-7-16(17)11-15/h3-13H,1-2H3,(H2,22,26)/t13-/m0/s1
No information available.
Summary of Clinical Use Click here for help
A pivotal, Phase 2B dose-ranging, efficacy study is underway comparing three doses of ATB-346 to placebo in patients with osteoarthritis of the knee. Four Phase 1 and 2 clinical studies have been completed, including part 1 of the ongoing study. The first Phase 2B study (see NCT03291418) showed that GI toxicity with ATB-346 is markedly reduced (compared to naproxen) following 14 days of treatment, whilst producing the same magnitude of COX inhibition [8].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03291418 To Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects Phase 1/Phase 2 Interventional Antibe Therapeutics Inc.